Hepatitis B Vaccine (Recombinant)

MARCH Phase 2 study shows 39% and 46% HBsAg loss in low baseline HBsAg participants with tobevibart + elebsiran and tobevibart + elebsiran + PEG-IFNα, respectively. No new safety concerns; TEAEs mild to moderate. Functional cure data expected Q2 2025.

Vir Biotechnology announced promising hepatitis B surface antigen loss rates in MARCH Phase 2 study, supporting further development towards a functional cure. Data to be presented at AASLD on November 18.

Vir Biotechnology announced end-of-treatment data from MARCH Phase 2 study, showing promising HBsAg loss rates with tobevibart and elebsiran combinations in chronic hepatitis B patients, with 39% and 46% HBsAg loss in low baseline HBsAg participants for doublet and triplet regimens, respectively.

39% of participants with low baseline HBsAg achieved HBsAg loss with tobevibart + elebsiran, and 46% with tobevibart + elebsiran + pegylated interferon alfa. No new safety concerns were identified, and treatment-emergent adverse events were generally mild to moderate. MARCH Part B study results presented at AASLD The Liver Meeting®. Key functional cure data from 24-week follow-up expected in Q2 2025.

Vir Biotechnology's Phase 2 trial for chronic hepatitis B treatment showed significant HBsAg loss rates with tobevibart and elebsiran, with or without pegylated interferon alfa. The company aims for a functional cure by Q2 2025, with ongoing progress in hepatitis programs and T-cell engager trials. Financial stability and strategic restructuring support continued R&D efforts despite revenue challenges.

Vir bolstered its clinical pipeline with three potential best-in-class dual-masked T-cell engagers in oncology and focused on infectious diseases. The company welcomed Jason O'Byrne as CFO and anticipates critical data in hepatitis programs in Q4 and initial clinical data from T-cell engagers in Q1 2025.

Precision BioSciences receives first approval for PBGENE-HBV clinical trial in Moldova, targeting chronic hepatitis B with in vivo gene editing.

Vir Biotechnology to present Phase 2 SOLSTICE trial data on tobevibart and elebsiran for chronic hepatitis delta at AASLD's The Liver Meeting in San Diego, Nov 15-19, 2024.